EXAS · CIK 0001124140 · operating
Exact Sciences Corporation operates in cancer diagnostics and screening, providing DNA-based tests designed to detect cancer and pre-cancerous conditions across multiple disease stages. The company's flagship product, Cologuard, is a non-invasive stool-based screening test that detects colorectal cancer and pre-cancer through DNA and hemoglobin biomarkers. The company also offers Cologuard Plus Tests and Cancerguard Test for additional screening applications, as well as a range of genetic testing services to assess inherited cancer risk.
Beyond screening, Exact Sciences provides oncology-focused diagnostic tests for treatment selection and monitoring. Its Oncotype DX product line includes assays for breast cancer recurrence risk assessment, ductal carcinoma in situ (DCIS) scoring, and colon cancer staging. The company also markets OncoExTra and Oncodetect tests for advanced tumor profiling and OncoExTra Test for metastatic disease treatment selection. These tests support clinical decision-making at multiple points along the cancer care pathway, from risk stratification through recurrence monitoring.
The company operates with approximately 7,100 full-time employees and maintains a global presence, with primary operations in the United States. Exact Sciences holds license agreements with Mayo Foundation for Medical Education and Research and Johns Hopkins University, and maintains partnerships with entities including Freenome Holdings, Inc., which inform its product development and research initiatives.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.10 | $-1.10 | +76.4% | |
| 2024 | $-4.67 | $-4.67 | -313.3% | |
| 2023 | $-1.13 | $-1.13 | +68.1% | |
| 2021 | $-3.54 | $-3.54 | -26.9% | |
| 2020 | $-2.79 | $-2.79 | -616.7% | |
| 2019 | $0.54 | $0.56 | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-13 | 0001124140-26-000011 | SEC ↗ |
| 2024-12-31 | 2025-02-19 | 0001124140-25-000020 | SEC ↗ |
| 2023-12-31 | 2024-02-21 | 0001124140-24-000012 | SEC ↗ |
| 2022-12-31 | 2023-02-21 | 0001124140-23-000014 | SEC ↗ |
| 2021-12-31 | 2022-02-22 | 0001124140-22-000022 | SEC ↗ |
| 2020-12-31 | 2021-02-16 | 0001124140-21-000029 | SEC ↗ |
| 2019-12-31 | 2020-02-21 | 0001124140-20-000010 | SEC ↗ |
| 2018-12-31 | 2019-02-21 | 0001558370-19-000854 | SEC ↗ |
| 2017-12-31 | 2018-02-22 | 0001558370-18-000941 | SEC ↗ |
| 2016-12-31 | 2017-02-21 | 0001558370-17-000714 | SEC ↗ |
| 2015-12-31 | 2016-02-24 | 0001558370-16-003446 | SEC ↗ |